Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Teva Pharmaceutical Industries stock has delivered a very strong 310.8% return over the past three years, yet the current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a large discount while market multiples look closer to fair.
-
A roughly 3x gain over three years can reset expectations, so recent buyers may be taking on a very different risk profile than those who entered earlier in the move.
-
Progress in higher value biopharmaceuticals, including programs like TEV-408 and new biosimilar partnerships, can support cash flow expectations. At the same time, execution risk around the pipeline and regulatory outcomes may weigh on how reliable those future cash flows appear.
-
Teva screens as undervalued on 4 of 6 checks, a mixed picture rather than a clear bargain or clear overvaluation, according to its value score of 4/6 .
The issue now is whether Teva Pharmaceutical Industries' recent share price sits far enough below the DCF based intrinsic value estimate to compensate investors for the risks embedded in its turnaround and pipeline.
Does Teva Pharmaceutical Industries Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model values Teva Pharmaceutical Industries by projecting the cash it may generate for shareholders and discounting that back to today. In this approach, Teva's latest twelve month free cash flow of about $1.2b is treated as recovering and growing over time, which leads to an estimated intrinsic value of around $64 per share.
Compared with the current share price, that calculation implies roughly a 48.7% discount, so the stock screens as undervalued on this model. The DCF assumes that pipeline and biosimilar efforts translate into higher future free cash flow, and that those dollars remain available to equity holders after debt servicing. Because the recent move to advance TEV-408 into a Phase 2b trial adds another potential high value asset to Teva Pharmaceutical Industries, the market's lower pricing relative to this cash flow based estimate suggests investors are still applying a meaningful risk discount.
Overall, the Discounted Cash Flow view indicates Teva Pharmaceutical Industries stock currently looks undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Teva Pharmaceutical Industries is undervalued by 48.7%. Track this in your watchlist or portfolio , or discover 45 more high quality undervalued stocks .
Where Does Teva Pharmaceutical Industries Sit on Earnings?
P/E is a useful yardstick for Teva Pharmaceutical Industries because earnings are a key focus for investors watching its turnaround progress. Teva currently trades on a P/E of about 24.5x, which is higher than the wider pharmaceuticals industry average of 14.9x and also above the peer group average of 19.2x.
That premium aligns with a more tailored "fair" P/E of about 26.6x, which reflects Teva's specific mix of risks, margins, market position and size. The current multiple sits slightly below this fair ratio, so the stock does not screen as either clearly cheap or clearly expensive on earnings, even after recent attention on its biopharmaceutical and biosimilar pipeline.
On the P/E multiple, Teva Pharmaceutical Industries stock appears to be priced at around a fair level.
See what the numbers say about this price — find out in our valuation breakdown.
The Teva Pharmaceutical Industries Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Teva Pharmaceutical Industries take the valuation puzzle a step further by spelling out which paths for Teva Pharmaceutical Industries' future growth, margins and earnings would need to play out for the stock to be worth significantly more or less than today. Each narrative links its number to a clear view on how growth, profitability and risks could evolve. This gives you a reference point to revisit as new information about Teva Pharmaceutical Industries' progress emerges on the Community page.
On Teva Pharmaceutical Industries, the community is split between a growth-at-a-discount story and concerns that expectations sit too high.
Bull case: 19% undervalued
"Teva's diversified portfolio and expanding branded and biosimilar products are expected to drive steady, higher-margin growth and profitability amid demographic and regulatory tailwinds…"
Read the full Bull Case to see why Teva Pharmaceutical Industries could be undervalued
Bear case: 53% overvalued
"Heavy reliance on a narrow set of growth engines such as AUSTEDO, UZEDY and AJOVY, in indications where underdiagnosis and undertreatment are being actively addressed across the industry, could expose Teva to future competitive launches and reimbursement tightening that may cap pricing power and slow top line expansion, pressuring revenue growth targets…"
Read the full Bear Case to see why Teva Pharmaceutical Industries could be overvalued
Do you think there's more to the story for Teva Pharmaceutical Industries? Head over to our Community to see what others are saying!
The Bottom Line
For Teva Pharmaceutical Industries, the Discounted Cash Flow (DCF) view points to a large intrinsic value gap, while the P/E multiple suggests the stock is priced at about the right level relative to peers. That split reflects a market that is still cautious about how reliably future cash flows from the pipeline and biopharmaceutical push will materialise, even as earnings already support a mid range multiple. With broader checks painting a mixed picture rather than a clear opportunity, the key question from here is whether Teva Pharmaceutical Industries can execute on its higher value portfolio well enough to turn the current discount into realised cash generation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TEVA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
